Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Metastatic Breast Cancer
Female
Metastatic Breast Cancer
Trial Information
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
Inclusion Criteria:
- Patients that have received Abraxane chemotherapy greater than three months from the
time of chart review.
- Patients that have received taxane chemotherapy greater than three months from the
time of chart review.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
Describe patient demographics, disease and treatment characteristics.
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Jeffrey F Patton, M.D.
Investigator Role:
Study Chair
Investigator Affiliation:
Sarah Cannon Research Institute
Authority:
United States: Institutional Review Board
Study ID:
SCRI OUTCOMES 02
NCT ID:
NCT00876070
Start Date:
November 2008
Completion Date:
February 2011
Related Keywords:
- Metastatic Breast Cancer
- Metastatic Breast Cancer
- Breast Cancer
- MBC
- Abraxane
- Paclitaxel
- Taxol
- Docetaxel
- Taxotere
- Breast Neoplasms
Name | Location |
|---|---|
| Georgia Cancer Specialists | Decatur, Georgia 30033 |
| Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |
